News | March 03, 2022
Merck KGaA reports higher profits on strong volumes across its businesses
Company expects strong organic growth in sales, EBITDA in 2022
Company expects strong organic growth in sales, EBITDA in 2022
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years
Evonik invests in start-up to improve patient recovery after open-chest surgery
Resolv ER may remedy leading causes of blindness in adults
ICICI Direct’s analysis of Cipla’s Q3FY22 results
Medtech plays a vital role in the healthcare system and players in this field believe that the budget should address some of their concerns if India has to become a formidable player
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Subscribe To Our Newsletter & Stay Updated
